Gastric Neuroendocrine Tumor Market Report and Forecast 2025-2034
Description
The gastric neuroendocrine tumor market was valued at USD 1.85 Billion in 2024, driven by a supportive regulatory framework and growth in clinical trials across the 8 major markets. The market is expected to grow at a CAGR of 3.34% during the forecast period of 2025-2034, with the values likely to reach USD 2.57 Billion by 2034.
Gastric Neuroendocrine Tumor Market Overview
Gastric neuroendocrine tumors refer to gastric neoplasm that originates from enterochromaffin type cells (neuroendocrine cells in the gastric mucosa). They belong to a broader category of gastroenteropancreatic neuroendocrine tumors. Somatostatin analogs for controlling the tumor are one of the therapeutic options for this disease.
Gastric neuroendocrine tumors are rare but have witnessed increasing incidence over the years. The rising diagnosis rates of these tumors as a result of advancements in diagnostic technologies and better awareness among healthcare providers are contributing to the market growth. The increasing development and adoption of targeted therapies such as octreotide and lanreotide are further supporting the market expansion. Moreover, the rise in the number of clinical trials exploring novel therapies is anticipated to bolster market growth in the coming years.
Gastric Neuroendocrine Tumor Market Growth Drivers
Favorable Regulatory Environment to Impact Market Growth
The presence of a supportive regulatory framework is one of the primary factors, stimulating the growth of the market and attracting substantial investments to advance treatment for gastric neuroendocrine tumors. For instance, in February 2024, two clinical-stage radiopharmaceutical companies RadioMedix, Inc., and Orano Med announced that their Targeted Alpha Therapy called AlphaMedixTM (212Pb-DOTAMTATE) had received Breakthrough Therapy Designation (BTD) from the United States Food and Drug Administration (FDA) for the treatment of gastroenteropancreatic neuroendocrine tumors. Such designations are projected to accelerate the development and review of novel agents, which is likely to boost market growth.
Gastric Neuroendocrine Tumor Market Trends
The market is witnessing several trends and developments to improve the current scenario. Some of the notable trends are as follows:
Rising Awareness to Affect the Market Landscape Significantly
The market is witnessing increased awareness campaigns by medical societies and patient advocacy groups which is leading to better recognition of gastric neuroendocrine tumors' signs and symptoms and thus higher demand for effective therapies. For example, November 10th is celebrated as World NET Cancer Day to spread awareness for neuroendocrine tumors (NET). This day also helps in advocating for better access to care and treatment options for the disease.
Expansion of Clinical Trials Poised to Augment Gastric Neuroendocrine Tumor Market Demand
The growth in clinical trials exploring new drugs and combination therapies for gastric neuroendocrine tumors is a significant market trend. This surge in clinical research, with an emphasis on finding innovative treatment options like immunotherapy and gene therapy, is anticipated to boost the market growth in the forecast period.
Growing Adoption of Targeted and Systemic Therapies to Elevate the Gastric Neuroendocrine Tumor Market Value
One of the major market trends is the growing adoption of targeted therapies such as somatostatin analogs (octreotide and lanreotide) and tyrosine kinase inhibitors which is likely to elevate the market value in the coming years. Additionally, the introduction of newer systemic therapies like peptide receptor radionuclide therapy (PRRT) with Lutetium-177 is poised to support market expansion.
Advancements in Diagnostic and Imaging Techniques to Boost Gastric Neuroendocrine Tumor Market Size
The market is experiencing increasing advancements in imaging technologies that are improving the detection of gastric neuroendocrine tumors and aiding the market growth. Innovations in endoscopic ultrasound (EUS), magnetic resonance imaging (MRI), computed tomography (CT), and positron emission tomography (PET) scans are allowing earlier diagnosis and better treatment planning.
Gastric Neuroendocrine Tumor Market Segmentation
Market Breakup by Treatment Type
Market Segmentation Based on Treatment Type Covers a Significant Market Share
Based on the treatment type, the market is segmented into chemotherapy, immunotherapy, surgery, radiation therapy, and others. Chemotherapy is used in gastric neuroendocrine tumor cases where the tumor has spread to other parts of the body or in high-grade aggressive tumors. The commonly used chemotherapy drugs for gastric neuroendocrine tumors include streptozocin, doxorubicin, and cisplatin, among others. Immunotherapy such as immune checkpoint inhibitors is an emerging treatment option due to its potential to offer long-term control of the disease with fewer side effects.
Gastric Neuroendocrine Tumor Market Analysis by Region
The market segmentation by region includes the United States, EU-4 (Germany, France, Italy, Spain), and the United Kingdom, Japan, and India. The United States holds a significant market share owing to the rising awareness among healthcare providers and the general public about the disease and substantial investment in research and development to find effective gastric neuroendocrine tumor treatments. The market also benefits from the availability of advanced diagnostic technologies, such as PET/CT scans, endoscopic procedures, and biomarkers, which facilitate early detection and accurate diagnosis of gastric neuroendocrine tumors and ensure timely intervention. Additionally, the rising demand for personalized medicine and targeted therapies is expected to fuel the market growth in the country.
Leading Players in the Gastric Neuroendocrine Tumor Market
The key features of the market report comprise patent analysis, grants analysis, clinical trial analysis, funding and investment analysis, and strategic initiatives by the leading key players. The major companies in the market are as follows:
Novartis AG
Novartis, based in Basel, Switzerland, is a multinational pharmaceutical corporation that plays a crucial role in market growth. In January 2024, the company presented the findings of the Phase III NETTER-2 trial at the 2024 American Society of Clinical Oncology (ASCO) Gastrointestinal (GI) Cancers Symposium, revealing that the combination of Lutathera® and long-acting release (LAR) octreotide significantly reduced the risk of disease progression or death by 72% as the first-line treatment in patients with advanced gastroenteropancreatic neuroendocrine tumors.
Pfizer Inc.
Pfizer has a robust portfolio of medications across multiple therapeutic areas, including oncology. The company is actively involved in the development of novel therapies for rare and difficult-to-treat cancers such as gastric neuroendocrine tumors. Pfizer is leveraging its extensive research capabilities to explore targeted therapies and immuno-oncology agents in order to maintain its leading position in the market.
Boehringer Ingelheim International GmbH
Boehringer Ingelheim, headquartered in Ingelheim am Rhein, Germany, is a key player in the market. The company is known for its strong pipeline of novel agents for various cancers, including gastric neuroendocrine tumors. It is involved in the clinical development of a new targeted immunotherapy, BI 764532, which is an investigational DLL3 that targets IgG-like T-cell engager, for the treatment of relapsed gastrointestinal tract, urogenital tract, and skin neuroendocrine carcinomas (epNEC).
Eli Lilly and Company
American pharmaceutical company Eli Lilly and Company has a prominent presence in the market and is known for its strong focus on oncology, immunology, diabetes, and neuroscience. The company is actively engaged in the development of targeted treatments and immuno-oncology agents that might have the potential to treat gastric neuroendocrine tumors.
Other key players in the market include F. Hoffmann-La Roche Ltd.
Key Questions Answered in the Gastric Neuroendocrine Tumor Market Report
Gastric Neuroendocrine Tumor Market Overview
Gastric neuroendocrine tumors refer to gastric neoplasm that originates from enterochromaffin type cells (neuroendocrine cells in the gastric mucosa). They belong to a broader category of gastroenteropancreatic neuroendocrine tumors. Somatostatin analogs for controlling the tumor are one of the therapeutic options for this disease.
Gastric neuroendocrine tumors are rare but have witnessed increasing incidence over the years. The rising diagnosis rates of these tumors as a result of advancements in diagnostic technologies and better awareness among healthcare providers are contributing to the market growth. The increasing development and adoption of targeted therapies such as octreotide and lanreotide are further supporting the market expansion. Moreover, the rise in the number of clinical trials exploring novel therapies is anticipated to bolster market growth in the coming years.
Gastric Neuroendocrine Tumor Market Growth Drivers
Favorable Regulatory Environment to Impact Market Growth
The presence of a supportive regulatory framework is one of the primary factors, stimulating the growth of the market and attracting substantial investments to advance treatment for gastric neuroendocrine tumors. For instance, in February 2024, two clinical-stage radiopharmaceutical companies RadioMedix, Inc., and Orano Med announced that their Targeted Alpha Therapy called AlphaMedixTM (212Pb-DOTAMTATE) had received Breakthrough Therapy Designation (BTD) from the United States Food and Drug Administration (FDA) for the treatment of gastroenteropancreatic neuroendocrine tumors. Such designations are projected to accelerate the development and review of novel agents, which is likely to boost market growth.
Gastric Neuroendocrine Tumor Market Trends
The market is witnessing several trends and developments to improve the current scenario. Some of the notable trends are as follows:
Rising Awareness to Affect the Market Landscape Significantly
The market is witnessing increased awareness campaigns by medical societies and patient advocacy groups which is leading to better recognition of gastric neuroendocrine tumors' signs and symptoms and thus higher demand for effective therapies. For example, November 10th is celebrated as World NET Cancer Day to spread awareness for neuroendocrine tumors (NET). This day also helps in advocating for better access to care and treatment options for the disease.
Expansion of Clinical Trials Poised to Augment Gastric Neuroendocrine Tumor Market Demand
The growth in clinical trials exploring new drugs and combination therapies for gastric neuroendocrine tumors is a significant market trend. This surge in clinical research, with an emphasis on finding innovative treatment options like immunotherapy and gene therapy, is anticipated to boost the market growth in the forecast period.
Growing Adoption of Targeted and Systemic Therapies to Elevate the Gastric Neuroendocrine Tumor Market Value
One of the major market trends is the growing adoption of targeted therapies such as somatostatin analogs (octreotide and lanreotide) and tyrosine kinase inhibitors which is likely to elevate the market value in the coming years. Additionally, the introduction of newer systemic therapies like peptide receptor radionuclide therapy (PRRT) with Lutetium-177 is poised to support market expansion.
Advancements in Diagnostic and Imaging Techniques to Boost Gastric Neuroendocrine Tumor Market Size
The market is experiencing increasing advancements in imaging technologies that are improving the detection of gastric neuroendocrine tumors and aiding the market growth. Innovations in endoscopic ultrasound (EUS), magnetic resonance imaging (MRI), computed tomography (CT), and positron emission tomography (PET) scans are allowing earlier diagnosis and better treatment planning.
Gastric Neuroendocrine Tumor Market Segmentation
Market Breakup by Treatment Type
- Chemotherapy
- Immunotherapy
- Surgery
- Radiation Therapy
- Others
- Oral
- Parenteral
- Others
- Hospitals
- Clinics
- Diagnostic Centers
- Research Laboratories
- Others
- United States
- EU-4 and the United Kingdom
- Germany
- France
- Italy
- Spain
- United Kingdom
- Japan
- India
Market Segmentation Based on Treatment Type Covers a Significant Market Share
Based on the treatment type, the market is segmented into chemotherapy, immunotherapy, surgery, radiation therapy, and others. Chemotherapy is used in gastric neuroendocrine tumor cases where the tumor has spread to other parts of the body or in high-grade aggressive tumors. The commonly used chemotherapy drugs for gastric neuroendocrine tumors include streptozocin, doxorubicin, and cisplatin, among others. Immunotherapy such as immune checkpoint inhibitors is an emerging treatment option due to its potential to offer long-term control of the disease with fewer side effects.
Gastric Neuroendocrine Tumor Market Analysis by Region
The market segmentation by region includes the United States, EU-4 (Germany, France, Italy, Spain), and the United Kingdom, Japan, and India. The United States holds a significant market share owing to the rising awareness among healthcare providers and the general public about the disease and substantial investment in research and development to find effective gastric neuroendocrine tumor treatments. The market also benefits from the availability of advanced diagnostic technologies, such as PET/CT scans, endoscopic procedures, and biomarkers, which facilitate early detection and accurate diagnosis of gastric neuroendocrine tumors and ensure timely intervention. Additionally, the rising demand for personalized medicine and targeted therapies is expected to fuel the market growth in the country.
Leading Players in the Gastric Neuroendocrine Tumor Market
The key features of the market report comprise patent analysis, grants analysis, clinical trial analysis, funding and investment analysis, and strategic initiatives by the leading key players. The major companies in the market are as follows:
Novartis AG
Novartis, based in Basel, Switzerland, is a multinational pharmaceutical corporation that plays a crucial role in market growth. In January 2024, the company presented the findings of the Phase III NETTER-2 trial at the 2024 American Society of Clinical Oncology (ASCO) Gastrointestinal (GI) Cancers Symposium, revealing that the combination of Lutathera® and long-acting release (LAR) octreotide significantly reduced the risk of disease progression or death by 72% as the first-line treatment in patients with advanced gastroenteropancreatic neuroendocrine tumors.
Pfizer Inc.
Pfizer has a robust portfolio of medications across multiple therapeutic areas, including oncology. The company is actively involved in the development of novel therapies for rare and difficult-to-treat cancers such as gastric neuroendocrine tumors. Pfizer is leveraging its extensive research capabilities to explore targeted therapies and immuno-oncology agents in order to maintain its leading position in the market.
Boehringer Ingelheim International GmbH
Boehringer Ingelheim, headquartered in Ingelheim am Rhein, Germany, is a key player in the market. The company is known for its strong pipeline of novel agents for various cancers, including gastric neuroendocrine tumors. It is involved in the clinical development of a new targeted immunotherapy, BI 764532, which is an investigational DLL3 that targets IgG-like T-cell engager, for the treatment of relapsed gastrointestinal tract, urogenital tract, and skin neuroendocrine carcinomas (epNEC).
Eli Lilly and Company
American pharmaceutical company Eli Lilly and Company has a prominent presence in the market and is known for its strong focus on oncology, immunology, diabetes, and neuroscience. The company is actively engaged in the development of targeted treatments and immuno-oncology agents that might have the potential to treat gastric neuroendocrine tumors.
Other key players in the market include F. Hoffmann-La Roche Ltd.
Key Questions Answered in the Gastric Neuroendocrine Tumor Market Report
- What was the gastric neuroendocrine tumor market value in 2024?
- What is the gastric neuroendocrine tumor market forecast outlook for 2025-2034?
- What are the regional markets covered in the EMR report?
- What is market segmentation based on treatment type?
- What is the market breakup based on the route of administration?
- Who are the major end users in the market?
- What are the major factors aiding the gastric neuroendocrine tumor market demand?
- How has the market performed so far and how is it anticipated to perform in the coming years?
- What are the market's major drivers, opportunities, and restraints?
- Which regional market is expected to lead the market share in the forecast period?
- Which country is expected to experience expedited growth during the forecast period?
- How do the prevalence and incidence of gastric neuroendocrine tumors affect the market landscape?
- What are the major gastric neuroendocrine tumor market trends?
- How does the rise in the geriatric population impact the market size?
- Which treatment type will dominate the market share?
- Which route of administration is expected to have a high market value in the coming years?
- Which end user is projected to contribute to the highest market growth?
- Who are the key players involved in the gastric neuroendocrine tumor market?
- What is the patent landscape of the market?
- What are the current unmet needs and challenges in the market?
- How are partnerships, collaborations, mergers and acquisitions among the key market players shaping the market dynamics?
Table of Contents
400 Pages
- 1 Preface
- 1.1 Objectives of the Study
- 1.2 Key Assumptions
- 1.3 Report Coverage – Key Segmentation and Scope
- 1.4 Research Methodology
- 2 Executive Summary
- 3 Gastric Neuroendocrine Tumor Market Overview – 8 Major Markets
- 3.1 Gastric Neuroendocrine Tumor Market Historical Value (2018-2024)
- 3.2 Gastric Neuroendocrine Tumor Market Forecast Value (2025-2034)
- 4 Vendor Positioning Analysis
- 4.1 Key Vendors
- 4.2 Prospective Leaders
- 4.3 Niche Leaders
- 4.4 Disruptors
- 5 Gastric Neuroendocrine Tumor Overview
- 5.1 Guidelines and Stages
- 5.2 Pathophysiology
- 5.3 Screening and Diagnosis
- 5.4 Treatment Pathway
- 6 Patient Profile
- 6.1 Patient Profile Overview
- 6.2 Patient Psychology and Emotional Impact Factors
- 6.3 Risk Assessment and Treatment Success Rate
- 7 Gastric Neuroendocrine Tumor Market - Epidemiology Scenario and Forecast – 8 Major Markets
- 7.1 8MM Epidemiology Scenario Overview (2018-2034)
- 7.1.1 Prevalence, by Country
- 7.1.1.1 United States
- 7.1.1.2 United Kingdom
- 7.1.1.3 EU4
- 7.1.1.4 India
- 7.1.1.5 Japan
- 7.1.2 Diagnosed Cases, by Country
- 7.1.2.1 United States
- 7.1.2.2 United Kingdom
- 7.1.2.3 EU4
- 7.1.2.4 India
- 7.1.2.5 Japan
- 7.1.3 Treatment Seeking Rate, by Country
- 7.1.3.1 United States
- 7.1.3.2 United Kingdom
- 7.1.3.3 EU4
- 7.1.3.4 India
- 7.1.3.5 Japan
- 8 Gastric Neuroendocrine Tumor Market Landscape – 8 Major Markets
- 8.1 Gastric Neuroendocrine Tumor Market: Developers Landscape
- 8.1.1 Analysis by Year of Establishment
- 8.1.2 Analysis by Company Size
- 8.1.3 Analysis by Region
- 8.2 Gastric Neuroendocrine Tumor Market: Product Landscape
- 8.2.1 Analysis by Treatment Type
- 8.2.2 Analysis by Route of Administration
- 9 Gastric Neuroendocrine Tumor Market Challenges and Unmet Needs
- 9.1 Treatment Pathway Challenges
- 9.2 Compliance and Drop-Out Analysis
- 9.3 Awareness and Prevention Gaps
- 10 Cost of Treatment
- 11 Gastric Neuroendocrine Tumor Market Dynamics
- 11.1 Market Drivers and Constraints
- 11.2 SWOT Analysis
- 11.2.1 Strengths
- 11.2.2 Weaknesses
- 11.2.3 Opportunities
- 11.2.4 Threats
- 11.3 PESTEL Analysis
- 11.3.1 Political
- 11.3.2 Economic
- 11.3.3 Social
- 11.3.4 Technological
- 11.3.5 Legal
- 11.3.6 Environment
- 11.4 Porter’s Five Forces Model
- 11.4.1 Bargaining Power of Suppliers
- 11.4.2 Bargaining Power of Buyers
- 11.4.3 Threat of New Entrants
- 11.4.4 Threat of Substitutes
- 11.4.5 Degree of Rivalry
- 11.5 Key Demand Indicators
- 11.6 Key Price Indicators
- 11.7 Industry Events, Initiatives, and Trends
- 11.8 Value Chain Analysis
- 12 Gastric Neuroendocrine Tumor Market Segmentation (218-2034) - 8 Major Markets
- 12.1 Gastric Neuroendocrine Tumor Market (2018-2034) by Treatment Type
- 12.1.1 Market Overview
- 12.1.2 Chemotherapy
- 12.1.3 Immunotherapy
- 12.1.4 Surgery
- 12.1.5 Radiation Therapy
- 12.1.6 Others
- 12.2 Gastric Neuroendocrine Tumor Market (2018-2034) by Route of Administration
- 12.2.1 Market Overview
- 12.2.2 Oral
- 12.2.3 Parenteral
- 12.2.4 Others
- 12.3 Gastric Neuroendocrine Tumor Market (2018-2034) by End User
- 12.3.1 Market Overview
- 12.3.2 Hospitals
- 12.3.3 Clinics
- 12.3.4 Diagnostic Centers
- 12.3.5 Research Laboratories
- 12.3.6 Others
- 12.4 Gastric Neuroendocrine Tumor Market (2018-2034) by Region
- 12.4.1 Market Overview
- 12.4.2 United States
- 12.4.3 EU-4 and the United Kingdom
- 12.4.3.1 Germany
- 12.4.3.2 France
- 12.4.3.3 Italy
- 12.4.3.4 Spain
- 12.4.3.5 United Kingdom
- 12.4.4 Japan
- 12.4.5 India
- 13 United States Gastric Neuroendocrine Tumor Market (218-2034)
- 13.1 United States Gastric Neuroendocrine Tumor Market Historical Value (2018-2024)
- 13.2 United States Gastric Neuroendocrine Tumor Market Forecast Value (2025-2034)
- 13.3 United States Gastric Neuroendocrine Tumor Market (2018-2034) by Treatment Type
- 13.3.1 Market Overview
- 13.3.2 Chemotherapy
- 13.3.3 Immunotherapy
- 13.3.4 Surgery
- 13.3.5 Radiation Therapy
- 13.3.6 Others
- 13.4 United States Gastric Neuroendocrine Tumor Market (2018-2034) by Route of Administration
- 13.4.1 Market Overview
- 13.4.2 Oral
- 13.4.3 Parenteral
- 13.4.4 Others
- 13.5 United States Gastric Neuroendocrine Tumor Market (2018-2034) by End User
- 13.5.1 Market Overview
- 13.5.2 Hospitals
- 13.5.3 Clinics
- 13.5.4 Diagnostic Centers
- 13.5.5 Research Laboratories
- 13.5.6 Others
- 14 EU-4 and United Kingdom Gastric Neuroendocrine Tumor Market (218-2034)
- 14.1 EU-4 and United Kingdom Gastric Neuroendocrine Tumor Market Historical Value (2018-2024)
- 14.2 EU-4 and United Kingdom Gastric Neuroendocrine Tumor Market Forecast Value (2025-2034)
- 14.3 EU-4 and United Kingdom Gastric Neuroendocrine Tumor Market (2018-2034) by Treatment Type
- 14.3.1 Market Overview
- 14.3.2 Chemotherapy
- 14.3.3 Immunotherapy
- 14.3.4 Surgery
- 14.3.5 Radiation Therapy
- 14.3.6 Others
- 14.4 EU-4 and United Kingdom Gastric Neuroendocrine Tumor Market (2018-2034) by Route of Administration
- 14.4.1 Market Overview
- 14.4.2 Oral
- 14.4.3 Parenteral
- 14.4.4 Others
- 14.5 EU-4 and United Kingdom Gastric Neuroendocrine Tumor Market (2018-2034) by End User
- 14.5.1 Market Overview
- 14.5.2 Hospitals
- 14.5.3 Clinics
- 14.5.4 Diagnostic Centers
- 14.5.5 Research Laboratories
- 14.5.6 Others
- 15 Japan Gastric Neuroendocrine Tumor Market
- 15.1 Japan Gastric Neuroendocrine Tumor Market Historical Value (2018-2024)
- 15.2 Japan Gastric Neuroendocrine Tumor Market Forecast Value (2025-2034)
- 15.3 Japan Gastric Neuroendocrine Tumor Market (2018-2034) by Treatment Type
- 15.3.1 Market Overview
- 15.3.2 Chemotherapy
- 15.3.3 Immunotherapy
- 15.3.4 Surgery
- 15.3.5 Radiation Therapy
- 15.3.6 Others
- 15.4 Japan Gastric Neuroendocrine Tumor Market (2018-2034) by Route of Administration
- 15.4.1 Market Overview
- 15.4.2 Oral
- 15.4.3 Parenteral
- 15.4.4 Others
- 15.5 Japan Gastric Neuroendocrine Tumor Market (2018-2034) by End User
- 15.5.1 Market Overview
- 15.5.2 Hospitals
- 15.5.3 Clinics
- 15.5.4 Diagnostic Centers
- 15.5.5 Research Laboratories
- 15.5.6 Others
- 16 India Gastric Neuroendocrine Tumor Market
- 16.1 India Gastric Neuroendocrine Tumor Market Historical Value (2018-2024)
- 16.2 India Gastric Neuroendocrine Tumor Market Forecast Value (2025-2034)
- 16.3 India Gastric Neuroendocrine Tumor Market (2018-2034) by Treatment Type
- 16.3.1 Market Overview
- 16.3.2 Chemotherapy
- 16.3.3 Immunotherapy
- 16.3.4 Surgery
- 16.3.5 Radiation Therapy
- 16.3.6 Others
- 16.4 India Gastric Neuroendocrine Tumor Market (2018-2034) by Route of Administration
- 16.4.1 Market Overview
- 16.4.2 Oral
- 16.4.3 Parenteral
- 16.4.4 Others
- 16.5 India Gastric Neuroendocrine Tumor Market (2018-2034) by End User
- 16.5.1 Market Overview
- 16.5.2 Hospitals
- 16.5.3 Clinics
- 16.5.4 Diagnostic Centers
- 16.5.5 Research Laboratories
- 16.5.6 Others
- 17 Regulatory Framework
- 17.1 Regulatory Overview
- 17.2 US FDA
- 17.3 EU EMA
- 17.4 Japan PMDA
- 17.5 India CDSCO
- 17.6 Others
- 18 Patent Analysis
- 18.1 Analysis by Cancer Type of Patent
- 18.2 Analysis by Publication Year
- 18.3 Analysis by Issuing Authority
- 18.4 Analysis by Patent Age
- 18.5 Analysis by CPC Analysis
- 18.6 Analysis by Patent Valuation
- 19 Clinical Trials Analysis
- 19.1 Analysis by Trial Registration Year
- 19.2 Analysis by Trial Status
- 19.3 Analysis by Trial Phase
- 19.4 Analysis by Therapeutic Area
- 19.5 Analysis by Geography
- 20 Grants Analysis
- 20.1 Analysis by Year
- 20.2 Analysis by Amount Awarded
- 20.3 Analysis by Issuing Authority
- 20.4 Analysis by Grant Application
- 20.5 Analysis by Funding Institute
- 20.6 Analysis by NIH Departments
- 20.7 Analysis by Recipient Organization
- 21 Funding and Investment Analysis
- 21.1 Analysis by Funding Instances
- 21.2 Analysis by Treatment Type of Funding
- 21.3 Analysis by Funding Amount
- 21.4 Analysis by Leading Players
- 21.5 Analysis by Leading Investors
- 21.6 Analysis by Geography
- 22 Strategic Initiatives
- 22.1 Analysis by Partnership Instances
- 22.2 Analysis by Treatment Type of Partnership
- 22.3 Analysis by Leading Players
- 22.4 Analysis by Geography
- 23 Supplier Landscape
- 23.1 Market Share Analysis, By Region (Top 5 Companies)
- 23.2 Novartis AG
- 23.2.1 Financial Analysis
- 23.2.2 Product Portfolio
- 23.2.3 Demographic Reach and Achievements
- 23.2.4 Companies News and Developments
- 23.2.5 Certifications
- 23.3 Pfizer Inc.
- 23.3.1 Financial Analysis
- 23.3.2 Product Portfolio
- 23.3.3 Demographic Reach and Achievements
- 23.3.4 Companies News and Developments
- 23.3.5 Certifications
- 23.4 Boehringer Ingelheim International GmbH
- 23.4.1 Financial Analysis
- 23.4.2 Product Portfolio
- 23.4.3 Demographic Reach and Achievements
- 23.4.4 Companies News and Developments
- 23.4.5 Certifications
- 23.5 Eli Lilly and Company
- 23.5.1 Financial Analysis
- 23.5.2 Product Portfolio
- 23.5.3 Demographic Reach and Achievements
- 23.5.4 Companies News and Developments
- 23.5.5 Certifications
- 23.6 F-Hoffmann-La Roche Ltd,
- 23.6.1 Financial Analysis
- 23.6.2 Product Portfolio
- 23.6.3 Demographic Reach and Achievements
- 23.6.4 Companies News and Developments
- 23.6.5 Certifications
- 24 Gastric Neuroendocrine Tumor Treatment Drugs - Distribution Model (Additional Insight)
- 24.1 Overview
- 24.2 Potential Distributors
- 24.3 Key Parameters for Distribution Partner Assessment
- 25 Key Opinion Leaders (KOL) Insights (Additional Insight)
- 26 Payment Methods (Additional Insight)
- 26.1 Government Funded
- 26.2 Private Insurance
- 26.3 Out-of-Pocket
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
